Actively Recruiting
Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis
Led by Barnet Dulaney Perkins Eye Centers · Updated on 2025-05-01
300
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
Sponsors
B
Barnet Dulaney Perkins Eye Centers
Lead Sponsor
A
Alcon, a Novartis Company
Collaborating Sponsor
AI-Summary
What this Trial Is About
Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis
CONDITIONS
Official Title
Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects with history of combined CEIOL/OMNI/Hydrus surgery chosen based on using more than one medication pre-operatively
- Have glaucoma
- At least 3 years of follow-up data available
You will not qualify if you...
- Patients with angle closure glaucoma or secondary glaucoma due to neovascularization, uveitis, congenital glaucoma, or congenital anomalies
- Patients with refractory cystoid macular edema (CME) lasting 3 months or more after surgery
- Patients lacking complete intraocular pressure, medication records, or visual field data post-operatively
- Prior incisional eye surgery or minimally invasive glaucoma surgery (MIGS)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Barnet Dulaney Perkins Eye Center
Mesa, Arizona, United States, 85206
Actively Recruiting
Research Team
D
Derek J Arnson, Master of Education
CONTACT
C
Christine Funke, Medical Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here